Institutional members access full text with Ovid®

Early Prescription Opioid Use for Musculoskeletal Disorders and Work Outcomes: A Systematic Review of the Literature.

Carnide, Nancy MSc, PhD (Candidate); Hogg-Johnson, Sheilah PhD; Côté, Pierre DC, PhD; Irvin, Emma BA; Van Eerd, Dwayne MSc, PhD (Candidate); Koehoorn, Mieke PhD; Furlan, Andrea MD, PhD
Clinical Journal of Pain: Post Acceptance: November 10, 2016
doi: 10.1097/AJP.0000000000000452
Review Article: PDF Only

Objectives: Musculoskeletal disorders (MSDs) are a common source of work disability. Opioid prescribing for MSDs has been on the rise, despite a lack of data on effectiveness. The objective was to conduct a systematic review to determine whether early receipt of opioids is associated with future work outcomes among workers with MSDs compared to other analgesics, no analgesics, or placebo.

Methods: MEDLINE, EMBASE, CINAHL, and CENTRAL were searched from inception to 2014 and reference lists were scanned. Studies were included if opioids were prescribed within 12 weeks of MSD onset. Eligible outcomes included absenteeism, work status, receiving disability payments, and functional status. Two reviewers independently reviewed articles for relevance, risk of bias, and data extraction using standardized forms. Data synthesis using best evidence synthesis methods was planned.

Results: Five historical cohort studies met the inclusion criteria, all including workers filing wage compensation claims. Four studies demonstrated a significant association between early opioids and prolonged work disability. One study found a shorter time between prescriptions to be associated with shorter work disability. However, all studies were found to be at a high risk of bias and a best evidence synthesis could not be conducted. The main limitations identified were with exposure measurement and control of confounding.

Discussion: Current literature suggests opioids provided within the first 12 weeks of onset of MSD are associated with prolonged work disability. However, the conclusions of these studies need testing in a high quality study that addresses the methodological shortcomings identified in the current review.

Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.